Minerva Neurosciences Inc (NERV) moved from Hold to Buy at Jefferies on August 14, 2026, following an upgrade.
Among one firm active over the past 90 days, one holds a bullish rating. As of October 30, 2026, five analysts place the consensus mean at $10.54, the median at $10.20 and the range at $7.07 to $14.70.
For Q4 FY2026, analysts expect EPS of -$0.14 and revenue of $0. The next earnings report is scheduled for March 9, 2027.
